{"id":"NCT00105469","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)","officialTitle":"A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% AzaSite Compared to 0.3% Tobramycin Ophthalmic Solution in the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-07","primaryCompletion":"2005-10","completion":"2005-10","firstPosted":"2005-03-15","resultsPosted":"2011-10-27","lastUpdate":"2013-12-16"},"enrollment":743,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Conjunctivitis"],"interventions":[{"type":"DRUG","name":"AzaSite","otherNames":[]},{"type":"DRUG","name":"Tobramycin","otherNames":[]}],"arms":[{"label":"AzaSite","type":"EXPERIMENTAL"},{"label":"Tobramycin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to tobramycin for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye are eligible. Subjects will be randomly assigned to the AzaSite group or Tobramycin group. Three visits will be required for the study.","primaryOutcome":{"measure":"Number of Participants Who Achieved Clinical Resolution at Visit 3","timeFrame":"Visit 3 (Day 6)","effectByArm":[{"arm":"AzaSite","deltaMin":127,"sd":null},{"arm":"Tobramycin","deltaMin":123,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":26,"countries":["United States"]},"refs":{"pmids":["17652708"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":365},"commonTop":[]}}